In a report released today, Edward Tenthoff from Piper Sandler maintained a Hold rating on Galera Therapeutics (GRTX – Research Report), with a price target of $0.50. The company’s shares closed yesterday at $0.25.
According to TipRanks, Tenthoff is a 5-star analyst with an average return of 10.1% and a 38.88% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Cue Biopharma, and Galera Therapeutics.
In addition to Piper Sandler, Galera Therapeutics also received a Hold from H.C. Wainwright’s Ram Selvaraju in a report issued yesterday. However, on August 11, Bank of America Securities downgraded Galera Therapeutics (NASDAQ: GRTX) to a Sell.
See Insiders’ Hot Stocks on TipRanks >>
GRTX market cap is currently $11M and has a P/E ratio of -0.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
Read More on GRTX:
- Galera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Galera Therapeutics downgraded to Neutral from Buy at Citi
- Galera Therapeutics reports Q2 EPS (48c), consensus (44c)
- Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- GRTX Earnings this Week: How Will it Perform?
